0.00Open0.70Pre Close0 Volume185 Open Interest3.50Strike Price0.00Turnover55.20%IV0.36%PremiumDec 20, 2024Expiry Date0.69Intrinsic Value100Multiplier23DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type0.9104Delta0.2802Gamma5.98Leverage Ratio-0.0024Theta0.0020Rho5.44Eff Leverage0.0017Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet